157 related articles for article (PubMed ID: 10928306)
1. Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: relation to side effects, psychosocial function and depression.
Gitlin MJ; Nuechterlein KH; Mintz J; Fogelson D; Bartzokis G; Ventura J; Subotnik K; Aravagiri M
Psychopharmacology (Berl); 2000 Mar; 148(4):350-4. PubMed ID: 10928306
[TBL] [Abstract][Full Text] [Related]
2. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
3. Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates.
McLaren S; Cookson JC; Silverstone T
Int Clin Psychopharmacol; 1992 Nov; 7(2):67-72. PubMed ID: 1487623
[TBL] [Abstract][Full Text] [Related]
4. Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate.
Marder SR; Aravagiri M; Wirshing WC; Wirshing DA; Lebell M; Mintz J
Schizophr Res; 2002 Jan; 53(1-2):25-30. PubMed ID: 11728835
[TBL] [Abstract][Full Text] [Related]
5. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G; Annable L; Campbell W
J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
[TBL] [Abstract][Full Text] [Related]
6. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
Chouinard G; Annable L; Ross-Chouinard A
Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
[No Abstract] [Full Text] [Related]
7. Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients.
Knights A; Okasha MS; Salih MA; Hirsch SR
Br J Psychiatry; 1979 Dec; 135():515-23. PubMed ID: 394794
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
[TBL] [Abstract][Full Text] [Related]
9. Clinical and social comparison of fluphenazine decanoate and flupenthixol decanoate in the community maintenance therapy of schizophrenia.
Kelly HB; Freeman HL; Banning B; Schiff AA
Int Pharmacopsychiatry; 1977; 12(1):54-64. PubMed ID: 406212
[TBL] [Abstract][Full Text] [Related]
10. Fluphenazine decanoate in acute and maintenance therapy of schizophrenia.
Altamura AC; Mauri MC; Guercetti G; Cazzullo CL
Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(5):613-23. PubMed ID: 3122268
[TBL] [Abstract][Full Text] [Related]
11. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
Walker CA
Pharmatherapeutica; 1983; 3(5):289-93. PubMed ID: 6133287
[TBL] [Abstract][Full Text] [Related]
12. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
Altamura AC; Mauri MC; Girardi T; Panetta B
Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
[TBL] [Abstract][Full Text] [Related]
13. Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics.
Mandel MR; Severe JB; Schooler NR; Gelenberg AJ; Mieske M
Arch Gen Psychiatry; 1982 Feb; 39(2):197-203. PubMed ID: 6121543
[TBL] [Abstract][Full Text] [Related]
14. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
Kong DS; Yeo SH
Pharmatherapeutica; 1989; 5(6):371-9. PubMed ID: 2687894
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate.
Viala A; Ba B; Durand A; Gouezo F; Hou N; Jørgensen A
Psychopharmacology (Berl); 1988; 94(3):293-7. PubMed ID: 2895936
[TBL] [Abstract][Full Text] [Related]
16. Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate.
Miller RS; Peterson GM; McLean S; Westhead TT; Gillies P
J Clin Pharm Ther; 1995 Apr; 20(2):55-62. PubMed ID: 7650075
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia.
Leong OK; Wong KE; Tay WK; Gill RC
Singapore Med J; 1989 Oct; 30(5):436-40. PubMed ID: 2575796
[TBL] [Abstract][Full Text] [Related]
18. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
19. A controlled one-year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Evaluation of results at 6 and 12 months' trial.
Dencker SJ; Frankenberg K; Malm U; Zell B
Acta Psychiatr Scand Suppl; 1973; 241():101-18. PubMed ID: 4147508
[No Abstract] [Full Text] [Related]
20. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
Roose K
Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]